Prognostic factors and outcomes of patients with advanced non-small-cell lung cancer treated with osimertinib: a retrospective database study
M. Pérol(Centre Léon Bérard), Andreas Bjerrum(Copenhagen University Hospital), C. Knott(NHS England), J. Edwards(Johnson & Johnson (United Kingdom)), P. Macouillard(UniCancer Group), J. Penton(Johnson & Johnson (United Kingdom)), L. Bosquet(UniCancer Group), Sophie José(NHS England), Irene Luccarini(Johnson & Johnson (Italy)), N.J. Perualila, Joris Diels(Janssen (Belgium)), Jan Sermon, C. Chouaïd(Université de Montpellier)
Cited by 0
Related Papers
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy
|AIDS|2014|597
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|The Lancet Oncology|2018|579